Antiviral effect of raltegravir on HTLV-1 carriers | Zendy

Ana Treviño | Zendy; Patricia Parra | Zendy; Tamara Bar-Magen | Zendy; Carmen Garrido | Zendy; Carmen de Mendoza | Zendy; Vincent Soriano | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antiviral effect of raltegravir on HTLV-1 carriers

Author(s) -

Ana Treviño,

Patricia Parra,

Tamara Bar-Magen,

Carmen Garrido,

Carmen de Mendoza,

Vincent Soriano

Publication year - 2011

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkr404

Subject(s) - raltegravir , integrase inhibitor , peripheral blood mononuclear cell , virology , tropical spastic paraparesis , viral load , human t lymphotropic virus , asymptomatic , integrase , asymptomatic carrier , medicine , biology , immunology , virus , myelopathy , in vitro , human immunodeficiency virus (hiv) , antiretroviral therapy , genetics , psychiatry , spinal cord

In vitro studies support that integrase inhibitors, such as raltegravir, may inhibit human T cell lymphotropic virus type 1 (HTLV-1) replication. However, this hypothesis has not been tested in vivo.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research